CCO Oncology Podcast

185 Épisodes

1. Expert Insight on Practice Changing From IGCS 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer

   Publié: 21/09/2021
2. Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address FAQs

   Publié: 24/08/2021
3. Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer

   Publié: 19/08/2021
4. Essential Biomarker Testing in GI Cancers

   Publié: 18/08/2021
5. CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions

   Publié: 05/08/2021
6. The Latest Advances and Guidance in Nonmetastatic Castration-Resistant Prostate Cancer

   Publié: 30/07/2021
7. Managing Serious Adverse Events Associated with BTK Inhibitor Treatment

   Publié: 27/07/2021
8. Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 2: Patient Strategies for Self-Management

   Publié: 27/07/2021
9. Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 1: Drug–Drug and Drug–Food Interactions

   Publié: 27/07/2021
10. BTK Inhibitors in CLL and Lymphomas: Overview and Current Indications

    Publié: 23/07/2021
11. Adverse Events Associated with BTK Inhibitor Treatment

    Publié: 23/07/2021
12. Radiopharmaceuticals in the Treatment of Metastatic Castration-Resistant Prostate Cancer

    Publié: 20/07/2021
13. Expert Answers to HCP Questions on CAR T-Cell Therapy

    Publié: 19/07/2021
14. How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on BCMA-Targeted Therapies

    Publié: 19/07/2021
15. How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on Selinexor, Venetoclax, and Melphalan Flufenamide

    Publié: 16/07/2021
16. Treatment Options for Patients With Multiple Myeloma After First Relapse

    Publié: 14/07/2021
17. Caring for Patients With Newly Diagnosed Multiple Myeloma

    Publié: 14/07/2021
18. Precision Medicine in Gynecologic Cancers: Expert Answers to Your Questions

    Publié: 12/07/2021
19. Expert Answers to Questions on Managing Neurofibromatosis Type 1 and MEK Inhibitors for NF1-Associated Plexiform Neurofibromas

    Publié: 12/07/2021
20. Expert Answers to Questions on PARP Inhibitor Combinations in Prostate Cancer

    Publié: 30/06/2021